Cholesterol metabolism, pancreatic β-cell function and diabetes

Area of Science:

• Endocrinology
• Metabolic Syndrome
• Molecular Biology

Background:

• Cholesterol is crucial for cell membrane integrity and function, particularly in pancreatic beta-cells responsible for insulin secretion.
• Disruptions in cellular cholesterol homeostasis can lead to beta-cell dysfunction and impaired glucose metabolism.
• The low-density lipoprotein receptor (LDL-R) is implicated in cholesterol accumulation within beta-cells, potentially contributing to dysfunction.

Purpose of the Study:

• To investigate whether hypocholesterolemic drugs, which often upregulate LDL-R, possess diabetogenic properties.
• To assess the impact of cholesterol-lowering therapies on the risk of new-onset diabetes (NOD) and glycemic control in diabetic patients.
• To clarify the role of cholesterol homeostasis in pancreatic beta-cell function and its modulation by different lipid-lowering drugs.

Main Methods:

• Review of clinical trial data and molecular evidence concerning cholesterol metabolism and pancreatic beta-cell function.
• Analysis of the association between statin therapy and the incidence of new-onset diabetes.
• Comparison of the effects of statins versus other lipid-lowering agents (ezetimibe, PCSK9 inhibitors) on diabetes risk.

Main Results:

• Statin therapy has been linked to an increased incidence of new-onset diabetes, with effects varying by statin type and dose.
• The cardiovascular benefits of statins generally outweigh the associated increased risk of diabetes.
• Clinical trials with ezetimibe and PCSK9 inhibitors have not shown an increased risk of developing diabetes.

Conclusions:

• Cholesterol homeostasis is critical for pancreatic beta-cell function in humans.
• Statins negatively impact human beta-cell function, potentially leading to diabetes.
• Other cholesterol-lowering therapies do not appear to share this diabetogenic effect, but long-term studies are needed.